On the stock market since 2021, it operates in the world of health and science. Now — the numbers.
The company closed last year at a loss: costs ran above sales. The picture changes only if spending is reined in.
Average growth of 311% a year over the last 3 years. Red columns mark years that ended in a loss.
Before the clock runs out, either sales must climb sharply or new money must come in. This is the most critical line in the whole picture.
angles, checked one by one.
The 3 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
Profit per Sale: The profit kept from each sale is thin.
The stock trades below its recent peak — about 13% off the top. A pullback, not a collapse.
Over the last 3 years, sales grew about 311% a year on average.
The company sells $1.1B a year; the problem isn’t sales — it’s costs running above that number.
A loss of $221.4M against $1.1B in annual sales.
At the current pace of spending, the cash lasts less than a year. After that, the company needs to find new money.
On our five-subject report card, KURIU sits in the middle of the class: some subjects shine, others don’t. The grade moves as the numbers move.
The takeaway: KURIU has solid sales but closed last year at a loss. The road back to profit runs through spending discipline.